With Cancer in Remission, What Is the New Normal for Patients?
CURE spoke with experts about what life is like for patients in the survivorship care period.
We Have Come a Long Way
CURE magazine's outgoing editor-in-chief, Dr. Debu Tripathy, reflects on 18 years of advances in cancer care, the impact of AI and the evolving future of oncology treatment.
The Dawn of a New Era in Cancer Treatment
New advancements in cancer treatment are reducing the need for radical surgeries, offering organ-sparing therapies and enhancing survivorship care and support for patients.
What Patients Need to Know About Appealing Insurance Denials
The CEO of Triage Cancer discussed the “best-kept secret” of the health care system in an interview with CURE.
Organ-Sparing Treatments Bring New Life After Cancer
Avoiding surgery for rectal cancer, Sarah Rack of Memphis traveled to Houston for treatment every three weeks for 18 months.
Erleada Combo Shows Comparable Quality of Life Outcomes in Prostate Cancer
A study found no significant HRQOL differences between Erleada-based therapies and ADT plus AAP for advanced castration-sensitive prostate cancer.
Breaking Down the CONVERGE Study of NBTXR3 in Stage 3 Unresectable NSCLC
The first participant has been dosed on the phase 2 CONVERGE study evaluating NBTXR3 in stage III, unresectable non–small cell lung cancer.
Carvykti Effective in Real-World Setting for Myeloma
The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.
